Chemoproteomic Covalent Ligand Discovery as the PROTAC-gonist: The Future of Targeted Degradation Medicines NEW #FirstReactions by Matthews Group discussing work by Dan Nomura & colleagues go.acs.org/ao1 Read it here: go.acs.org/ao2

AbbVie’s IV MCL-1 Inhibitor Suggests On-Target Cardiotoxicity | drughunters.com/4dM9Aj9 Read our case study on AbbVie’s MCL-1 inhibitor ABBV-467. Read the full article here | drughunters.com/4dM9Aj9

BMS-986365: A Next-Generation Oral AR Heterobifunctional Degrader for Drug-Resistant Prostate Cancer This full case study details how BMS-986365 was engineered to have low intrinsic agonism and exert direct antagonism of WT AR and more! Full Article: drughunters.com/4dIhx9d

Targeted Degradation of Protein Kinase A via a Stapled Peptide PROTAC | ACS Chemical Biology pubs.acs.org/doi/10.1021/ac…

Peptide-Mediated Small Molecule Lysosome-Targeting Chimeras for Targeted Degradation of Membrane and Intracellular Proteins | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9 | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

The French Medicinal Chemistry Society–SCT, an Historical Member of EFMC** - Deprez‐Poulain - ChemMedChem - Wiley Online Library …mistry-europe.onlinelibrary.wiley.com/doi/10.1002/cm…

Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression nature.com/articles/s4138…

Excited to share our latest work combining VHL and CRBN in a single trivalent PROTAC to boost protein degradation. Great #TPD collaboration with Georg Winter and Kristin Riching, led by Adam Bond Miquel & Celia in each lab Centre for Targeted Protein Degradation CeMM Promega Corporation doi.org/10.26434/chemr…

Structure‐Based Design of Bicyclic Helical Peptides That Target the Oncogene β‐Catenin - Yeste-Vázquez - Angewandte Chemie International Edition - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/an…

Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design pubs.rsc.org/en/content/art…

Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

Exploring Degradation of Intrinsically Disordered Protein Yes-Associated Protein Induced by Proteolysis TArgeting Chimeras | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

Development of Ligands and Degraders Targeting MAGE-A3 | Journal of the American Chemical Society pubs.acs.org/doi/10.1021/ja…

Selective Degradation of MLK3 by a Novel CEP1347-VHL-02 PROTAC Compound Limits the Oncogenic Potential of TNBC | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

In vivo–Active Soluble Epoxide Hydrolase–targeting PROTACs with Improved Potency and Stability biorxiv.org/content/10.110…

Heat Shock Protein 90 Interactome-Mediated Proteolysis Targeting Chimera (HIM-PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

Re-Evaluating PIN1 as a Therapeutic Target in Oncology Using Neutral Inhibitors and PROTACs | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

The New Frontier: Merging Molecular Glue Degrader and Antibody–Drug Conjugate Modalities To Overcome Strategic Challenges | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…